PET/MR multimodal analysis of brain blood flow and metabolism in carotid ischemia
Official title: PET/MR Multimodal Quantitative Imaging of Cerebral Ischemia With CBF and CMRGlc Assessment in Cephalo-Carotid Atherosclerosis
Run by Xuanwu Hospital, Beijing · NCT07079345 · Data updated 2026-11-12
This project uses combined PET and MRI scans to test whether measuring cerebral blood flow and glucose metabolism helps guide diagnosis and treatment for people with significant carotid artery narrowing who had a recent ischemic stroke or TIA.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | Men only |
| Enrollment | 200 (estimated) |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | August 1, 2028 |
| Study ends | August 1, 2028 |
| Registry record updated | November 20, 2025 |
| Trial ID | NCT07079345 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with unilateral anterior circulation carotid artery stenosis >70% who experienced a TIA or ischemic stroke in the affected territory within the past 12 months (and at least 3 weeks since the last event) and who can undergo PET/MR and follow scheduled follow-ups.
✕Probably not a fit
Patients with poor scan quality, other neurologic diseases that cause brain dysfunction, posterior circulation or bilateral high-grade stenosis, or inability to complete PET/MR imaging and follow-up visits are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will enroll 200 patients with unilateral anterior circulation carotid stenosis (>70%) who had a TIA or ischemic stroke in the affected territory more than 3 weeks but within 12 months. Participants will undergo PET/MR multimodal imaging at enrollment and have data collected again at 6- and 12-month follow-ups while receiving standard medical or surgical care. The project aims to optimize non-invasive quantitative algorithm models for cerebral blood flow (CBF) and cerebral metabolic rate of glucose (CMRGlc), identify new imaging markers, and relate quantitative metrics to clinical and treatment outcomes. Strict image quality control and exclusion of other neurologic disorders are used to ensure reliable quantitative measurements.
Why it matters
Potential benefit: If successful, this could provide better non-invasive imaging markers to personalize treatment decisions and monitor recovery for patients with carotid atherosclerosis and ischemic events.
How similar studies have gone: Prior PET and MRI studies have shown promise in mapping cerebral perfusion and metabolism, but fully integrated quantitative PET/MR models for guiding treatment in carotid stenosis remain relatively novel and are still being validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Angiography diagnosed unilateral anterior circulation head carotid artery stenosis, the diameter of the tube was reduced by \>70%, and the contralateral anterior circulation and bilateral posterior circulation did not exceed the stenosis of \>50% of the diameter reduction; 2. Must have had a transient ischemic attack or ischemic stroke within the area of the diseased vessel within the past 12 months, with the most recent onset being more than 3 weeks; 3. MRI showed no new infarct lesions in the skull; 4. There is no infarct lesion in the previous pontine area; 5. Research participants and informants can complete relevant examinations and follow-ups; 6. Informed consent signed by the study participant or his/her authorized representative; Exclusion Criteria: 1. Poor image quality caused by head movement or other reasons during scanning 2. Presence of other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal pressure hydrocephalus, etc.) 3. Presence of other systemic diseases that can cause cognitive impairment, such as hepatic insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid and vitamin B12 deficiency, specific infections (such as syphilis, HIV), alcohol and drug abuse, etc 4. Presence of other known diseases that may cause cognitive impairmentPresence of other known diseases that may cause cognitive impairment 5. Individuals with severe visual or hearing impairment, claustrophobia, or other conditions that prevent cooperation with MRI examination 6. Individuals suffering from diseases that make it impossible to cooperate with cognitive examinations 7. Refusal to sign the informed consent form at baseline
Where it's running
-
Xuanwu Hospitail, Capital Medical University
Beijing, China Recruiting
Study contacts
- Study coordinator: Bixiao Cui
- Email: bixiao1311@163.com
- Phone: 86-18311281311
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Paired VNS: How the Brain and Pupils Respond in Stroke Patients
This study tests real-time physiologic responses to paired VNS in adults with chronic motor impairment after ischemic stroke to help tailor dosing.
-
NeuroAiD test in mild to moderate ischemic stroke patients
This study tests whether adding MLC901 (NeuroAiD II) to standard stroke care helps adults who recently had an ischemic stroke recover better than standard care alone.
-
Using IMPROVE to guide carotid revascularisation decisions
This trial tests whether using the IMPROVE MRI-based score to select patients for carotid revascularisation is as good as standard care based mainly on stenosis degree, among people who have had a recent stroke or TIA due to carotid disease.
-
High-intensity interval versus moderate continuous exercise for stroke-related muscle loss
This will test whether high-intensity interval training (HIIT) or moderate-intensity continuous training (MCIT) better helps people 1–6 months after an ischemic stroke who have muscle loss regain muscle mass, strength, walking ability, and quality of life.
-
Test of adding a very low-dose edoxaban to standard antiplatelet therapy to prevent another stroke in adults 75 and older
This trial tests whether adding a tiny amount of edoxaban to aspirin or clopidogrel can better prevent a second stroke in people aged 75+ who recently had an ischemic stroke.
-
HR-MRI–Directed Tirofiban Therapy for Late-Window ICAS-LAA Stroke
We’re testing whether tirofiban plus dual antiplatelet therapy, guided by high-resolution MRI of the brain’s blood vessels, can help people with intracranial large-artery atherosclerosis strokes that begin more than 24 hours after onset.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.